New hope for tough prostate cancer: BNT324 takes on chemo

NCT ID NCT07365995

Recruiting now Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About 736 men will participate in this Phase 3 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BNT324 (also called DB-1311)
What this could lead to: If it works, BNT324 could offer a more effective treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not guaranteed. The new drug may not work better than current chemotherapy and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Florida Cancer Specialists- Fort Myers
RECRUITING

Fort Myers, Florida, 33901, United States
Florida Cancer Specialists- St. Petersburg
RECRUITING

St. Petersburg, Florida, 33701, United States
Florida Cancer Specialists- West Palm Beach
RECRUITING

West Palm Beach, Florida, 33401, United States
Illinois Cancer Specialists
RECRUITING

Niles, Illinois, 60714, United States
Illinois CancerCare PC
RECRUITING

Peoria, Illinois, 61615, United States
Maryland Oncology Hematology
RECRUITING

Rockville, Maryland, 20850, United States
Oncology/Hematology Care, Inc.
RECRUITING

Cincinnati, Ohio, 45242, United States
Rocky Mountain Cancer Centers
RECRUITING

Aurora, Colorado, 80012, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology - West Texas
RECRUITING

Wichita Falls, Texas, 76310, United States
Texas Oncology Gulf Coast
RECRUITING

Houston, Texas, 77024, United States
Texas Oncology South Austin
RECRUITING

Austin, Texas, 78731, United States
Texas Oncology, P.A. - Tyler
RECRUITING

Tyler, Texas, 75702, United States
Virginia Cancer Specialists PC
RECRUITING

Fairfax, Virginia, 22031, United States
Virginia Oncology Associates
RECRUITING

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.